Telix Pharmaceuticals Limited · ASX:TLX
Telix Pharmaceuticals — Telix Pharm — H1 2026 Earnings Presentation
27 slides from Telix Pharmaceuticals's earnings presentation, Aug 21, 2026
Slide 1: H1 2026 Interim Results Presentation
H1 2026 Interim Results Presentation August 20, 2026 ASX: TLX | NASDAQ: TLX Radiopharmaceutical manufacturing suite at TMS North Melbourne.
Slide 2: Presenters and Agenda
Presenters Agenda 1 CEO remarks Dr. Christian Behrenbruch Darren Smith Group Chief Financial 2 Financial update Managing Director Officer and Group CEO 3 Precision Medicine update 4 Therapeutics update Kevin Richardson Dr. David N. Cade 5 Q&A CEO, Telix Precision Chief Medical Officer Medicine 2
Slide 3: Forward looking statement
Forward looking statement This presentation should be read together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on
Slide 4: CEO remarks
CEO remarks Dr. Christian Behrenbruch Managing Director and Group CEO
Slide 5: Delivering against our 2026 strategic priorities
Delivering against our 2026 strategic priorities Strong execution across commercial, regulatory and clinical milestones Continue Launch new Advance five late-stage 1 2 3 commercial growth products clinical programs Delivered $388M in Secured Prescription Advancing Phase 3 therapeutics programs: sale
Slide 6: Continued commercial execution delivering growth
Continued commercial execution delivering growth Delivered 22% YoY revenue growth Group revenue 56% 22% 477 Market-leading position reinforced US$M by differentiated products 414 390 • Group revenue increased by 22% to $477M driven by strong demand 388 across our Precision Medicine 277 portfolio 310
Slide 7: Investments that expand our growth opportunities
Investments that expand our growth opportunities Increased R&D investments to drive meaningful growth EXPANDING INTO NEW INDICATIONS EXPANDING THE PIPELINE 1 New, small molecule candidate, TLX597-Tx with potentially best-in-class therapeutic profile5 Doubling the TAM by an incremental ~800,000+ Two
Slide 8: Expanding our manufacturing capabilities
Expanding our manufacturing capabilities Accelerating growth, de-risking execution and positioning for therapeutic launches Seneffe, Belgium GMP3 capacity to deliver therapeutics ARTMS QIS® technology, enabling highly efficient, cost-effective isotope Yokohama, Japan production ARTMS QIS® for isotop
Slide 9: Financial update
Financial update Darren Smith Chief Financial Officer
Slide 10: H1 2026 Key financial metrics
H1 2026 Key financial metrics Strong financial performance across growth, profitability and cash generation Revenue up 22% YoY1 EBITDA1 up 146% YoY R&D 26% of revenue1 $477M $52M $124M ($390M H1 2025) ($21M H1 2025) ($82M H1 2025) Precision Medicine Net profit up $41M YoY1 Cash balance up 78% Gross
Slide 11: H1 2026 Income statement (Group)
H1 2026 Income statement (Group) Strong execution driving 22% revenue growth and 148% EBITDA expansion YoY • Gross margin (GM) of 55%, increased H1 2026 % of H1 2025 % of YoY 2% YoY driven by disciplined pricing, US$M revenue US$M revenue change manufacturing & distribution efficiencies 22% Revenue
Slide 12: Strong revenue generation provides flexibility to reinvest
Strong revenue generation provides flexibility to reinvest Discretionary R&D investment driving new growth opportunities 1. TMS revenue from third parties. RLS is the largest component of Telix Manufacturing Solutions, TMS, contributing to third party revenue. Excludes revenues from Illuccix and Goz
Slide 13: Precision Medicine delivering growth and high margins
Precision Medicine delivering growth and high margins A highly profitable business delivering 26% YoY EBITDA growth • Revenue increased by 27% to $388M, driven by H1 2026 % of H1 2025 % of YoY continued adoption of Illuccix and Gozellix across revenue revenue change all markets US$M US$M • Strong de
Slide 14: Telix Manufacturing Solutions (TMS)
Telix Manufacturing Solutions (TMS) Investment in manufacturing and supply chain to scale up operations • TMS generated $89M of third-party H1 2026 H1 2025 revenue, up 10% YoY1, primarily driven by % of % of YoY RLS revenue revenue US$M US$M Change • RLS drove manufacturing and supply chain External
Slide 15: FY 2026 guidance
FY 2026 guidance Continued growth trajectory 950-970 Group revenue Revenue guidance range: $950M to $970M1 US$M 804 • Based on approved products and geographies • ~25% growth in Precision Medicine revenue • Potential upside pending regulatory approvals 517 • Revenue is expected to come in at the upp
Slide 16: Precision Medicine update
Precision Medicine update Kevin Richardson Precision Medicine, CEO
Slide 17: Precision Medicine portfolio delivered 31% YoY growth and 9% QoQ growth
Precision Medicine portfolio delivered 31% YoY growth and 9% QoQ growth Precision Medicine Global Sales US$M 31% 202 186 9% 16% 161 154 1% 155 4% 150 3% Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 17
Slide 18: Global infrastructure buildout to enable therapeutic launches
Global infrastructure buildout to enable therapeutic launches Building a global footprint with regulators, customers and payers Global approvals and launches on track • Illuccix has marketing authorizations in 24 countries1 • Commercially available in 22 countries2 • Completed Phase 3 study in China
Slide 19: Two first-in-class imaging agents for glioma and renal masses
Two first-in-class imaging agents for glioma and renal masses potentially first to market1,2 PDUFA date: September 11, 2026, BLA resubmission in progress Pixlumi ®3 MAA accepted in Europe Breakthrough Therapy Designation and Included in National Comprehensive Fast Track Designation Cancer Network (N
Slide 20: Current state: PSMA-PET transformed staging and BCR detection
Current state: PSMA-PET transformed staging and BCR detection Initial biopsy protocol has remained unchanged since the addition of MRI Current indications Current TAM: ~670,000 scans/year Future indications PSMA-PET scans Total addressable market (in thousands) BCR 460 Response to treatment nmCRPC I
Slide 21: Future state: revolutionizes biopsy decision-making
Future state: revolutionizes biopsy decision-making Potential to double the size of the existing PSMA market 1M+1 ~800,000 scans/year Move imaging utilization to the pre-biopsy stage BCR Response to Monitoring for Monitoring treatment nmCRPC mCRPC progression RLT selection response to RLT Initial st
Slide 22: Therapeutics update and outlook
Therapeutics update and outlook Dr. David N. Cade Chief Medical Officer
Slide 23: Pipeline: Late-stage and next-generation assets
Pipeline: Late-stage and “next-generation” assets PSMA: Prostate-specific membrane antigen. PDGFRα: Platelet-derived growth factor receptor alpha. CAIX: Carbonic anhydrase IX. mAb: Monoclonal antibody. LAT1: L-Type amino acid transporter 1. SM: Small molecule. CD66: Cluster of differentiation 66. FA
Slide 24: Progressing across early and late-stage therapeutics pipeline
Progressing across early and late-stage therapeutics pipeline Select pipeline highlights Delivering on our late-stage pipeline Advancing our earlier stage candidates TLX597-Tx, Phase 2 study for mCRPC completed enrollment in OPTIMAL-PSMA5, 120 patients, and Phase 3 study for TLX591-Tx for mCRPC star
Slide 25: Our multi-product prostate cancer therapy portfolio
Our multi-product prostate cancer therapy portfolio Aligned to disease state, patient needs and clinical opportunity Hormone-sensitive Castration-resistant Metastatic hormone-sensitive Metastatic castration-resistant Palliative TLX090-Tx TLX597-Tx TLX592-Tx TLX591-Tx Phase 3 OPTIMAL-e in PSMA+ Phase
Slide 26: A catalyst rich 2026
A catalyst rich 2026 Select milestones for Therapeutics candidates Select milestones for Precision Medicine candidates Regeneron collaboration Pixclara2 NDA resubmission (U.S.) TLX591-Tx for mCRPC, ProstACT Global Pixlumi2 MAA submission (Europe) • Part 1 data readout • Part 2 international site exp
Slide 27: Q&A
Q&A